Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/27/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. William G. Goodman

Wrong Dr. William G. Goodman?

Clinical Research Medical Directo...

Local Address: THOUSAND OAKS, California, United States
Amgen Inc
One Amgen Center Drive
Thousand Oaks, California 91320
United States

Company Description: Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The...   more
Background

Employment History

  • Professor of Medicine
    UCLA
  • Researcher
    UCLA
  • Professor of Medicine At the Division of Nephrology
    UCLA
  • Professor of Medicine
    David Geffen School of Medicine at the University of California , Los Angeles
  • Director of the Bone Histology Laboratory
    David Geffen School of Medicine at the University of California , Los Angeles
  • Kidney Specialist
    David Geffen School of Medicine at UCLA
  • Professor of Medicine and Kidney Specialist
    David Geffen School of Medicine at UCLA

Education

  • MD
  • medical degree
    The Ohio State University College of Medicine
37 Total References
Web References
BioDiscussion
www.biodiscussion.com, 19 Jan 2014 [cached]
William Goodman, MD BioDiscussion
...
William Goodman, MD Professor of Medicine Director, Bone, Histology and Molecular Bone Labs of the CRC UCLA School of Medicine
...
William Goodman, MD has documented that he/she has nothing to disclose.
ARANESP and Calcimimetics Clinical Data Presented At American Society Of Nephrology Meeting
www.immunex.com, 15 Oct 2000 [cached]
"ESRD patients suffer many complications from high levels of parathyroid hormone including vascular and soft tissue calcification," said William Goodman, M.D., professor of medicine, UCLA . "These encouraging results suggest that therapy with calcimimetics may provide great benefit to patients by suppressing the secretion of PTH and helping to normalize serum calcium and phosphorus."
Vital news for Kidney (renal), Heart, and Diabetes Patient
consume1.securesites.com, 5 Mar 2006 [cached]
William Goodman, MD, the UCLA researcher who is the lead author of the study, says that he puts his patients on a mixed regimen of Renagel and calcium in an effort to moderate calcium intake while containing costs.
Yahoo - Aksys home kidney dialysis system approved by FDA
biz.yahoo.com, 27 Mar 2002 [cached]
Dr. William Goodman, professor of medicine at the University of California at Los Angeles School of Medicine's division of nephrology, also said several small studies have shown that kidney patients who undergo frequent dialysis are healthier -- red blood cell counts are higher, blood pressure rates are better and their need for drugs is diminished or even eliminated.
"Three sessions a week of dialysis for four or four-and-a- half hours only provides about ten to 12 percent of normal kidney function," he said.
Goodman cautioned that there have not been any large-scale clinical studies of frequent dialysis schedules, noting that the National Institutes of Health has been skittish about funding such work."The economic impact would be overwhelming.Daily dialysis would double the cost of treatment in a dialysis center and Medicare pays for most of it," the UCLA professor said.
The Aksys system, which will be distributed to dialysis centers and not directly to patients, will be priced to fit in with current reimbursement levels, the company's CEO said.He said clinics are now paid $20,000 per-patient per year under Medicare and $35,000-45,000 from private insurers.
Mednet - CME, CHE | Management of Bone and Mineral Abnormalities in Chronic Kidney Disease
www.mednet.ca, 16 Aug 2012 [cached]
“This decline occurs before there is any elevation in serum phosphorus,†Dr. William Goodman, Professor of Medicine, David Geffen School of Medicine, noted. Abnormalities in vitamin D metabolism in turn adversely affect intestinal calcium transport. Thus, in Dr. Goodman’s view, elevations in PTH in early-stage CKD is an appropriate physiological response that helps maintain serum calcium levels. In both healthy individuals as well as in patients with mild to moderate CKD, phosphorus loading impairs the kidney’s production of 1,25-dihydroxyvitamin D3, while restricting phosphorus will increase its production.
The literature suggests that even if phosphorus level is normal, restricting phosphorus in the diet or through the use of phosphate binders will drive up 1,25-dihydroxy-vitamin D3 production and help prevent bone disease. Increases in 1,25-dihydroxyvitamin D3 levels correspond with subsequent reductions in plasma PTH levels, “so it is the change in circulating 1,25-dihydroxyvitamin D3 levels that mediates the reduction in PTH, not phosphorus per se,†Dr. Goodman indicated.
He also argued that patients with earlier-stage CKD are fundamentally different than those on dialysis, largely because they still have residual kidney function and they can excrete phosphorus. In patients who have mild to moderate CKD, serum phosphorus levels are usually normal, while serum calcium levels are typically in the lower range of normal, he added; and the fact that patients with mild CKD excrete relatively little calcium is a sign that the kidney is trying to conserve calcium. “I’m not arguing with the fact that phosphate restriction and phosphate binders are appropriate when serum phosphate levels are elevated,†Dr. Goodman stated.
...
Data supporting a non-calcium-based phosphate binder strategy are limited but one prospective studyâ€"the “treat-to-goal†trialâ€"showed that vascular calcification did not worsen over one year of follow-up in dialysis patients treated with sevelamer, whereas it did progress in patients treated with a calcium phosphate binder. “Theoretically, the use of lanthanum carbonate might have a similar beneficial effect because it is also calcium-free,†Dr. Goodman indicated, although this has not yet been demonstrated in a prospective trial.
However, he stated that the choice of a phosphate binding agent could influence progression of calcification once it is present, even though it is not clear how vascular calcification develops in the first place.
...
“Your choice of phosphate binder is going to be influenced very significantly by other biochemical abnormalities,†Dr. Goodman cautioned.
...
In an interview, Dr. Goodman also suggested that this agent might be equivalent in potency to the old aluminum-containing binders and more potent than calcium carbonate nor calcium acetate.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304